Cytokine Hub Classification of PASC, ME-CFS and other PASC-like Conditions

Abstract:

Background: Post-acute sequelae of COVID-19 (PASC) is a growing healthcare and economic concern affecting as many as 10%-30% of those infected with COVID-19. Though the symptoms have been well-documented, they significantly overlap with other common chronic inflammatory conditions which could confound treatment and therapeutic trials.

Methods: A total of 236 patients including 64 with post-acute sequelae of COVID-19 (PASC), 50 with myalgic encephalomyelitis-chronic fatigue syndrome (ME-CFS), 29 with post-treatment Lyme disease (PTLD), and 42 post-vaccine individuals with PASC-like symptoms (POVIP) were enrolled in the study. We performed a 14-plex cytokine/chemokine panel previously described to generate raw data that was normalized and run in a decision tree model using a Classification and Regression Tree (CART) algorithm. The algorithm was used to classify these conditions in distinct groups despite their similar symptoms.

Results: PASC, ME-CSF, POVIP, and Acute COVID-19 disease categories were able to be classified by our cytokine hub based CART algorithm with an average F1 score of 0.61 and high specificity (94%).

Conclusions: Proper classification of these inflammatory conditions with very similar symptoms is critical for proper diagnosis and treatment.

Source: Bruce K. Patterson, Jose Guevara-Coto, Edgar B. Francisco et al. Cytokine Hub Classification of PASC, ME-CFS and other PASC-like Conditions, 27 April 2022, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1598634/v1]  https://www.researchsquare.com/article/rs-1598634/v1 (Full text)

Recommendation for standardized medical care for children and adolescents with long COVID

Abstract:

This current consensus paper for long COVID complements the existing AWMF S1 guidelines for long COVID with a detailed overview on the various clinical aspects of long COVID in children and adolescents. Members of 19 different pediatric societies of the DGKJ convent and collaborating societies together provide expert-based recommendations for the clinical management of long COVID based on the currently available but limited academic evidence for long COVID in children and adolescents. It contains screening questions for long COVID and suggestions for a structured, standardized pediatric medical history and diagnostic evaluation for patients with suspected long COVID. A time and resource-saving questionnaire, which takes the clinical complexity of long COVID into account, is offered via the DGKJ and DGPI websites as well as additional questionnaires suggested for an advanced screening of specific neurocognitive and/or psychiatric symptoms including post-exertional malaise (PEM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). According to the individual medical history as well as clinical signs and symptoms a step by step diagnostic procedure and a multidisciplinary therapeutic approach are recommended.

Source: Töpfner N; Deutsche Gesellschaft für Pädiatrische Infektiologie e. V. (DGPI), Alberer M, Ankermann T; Gesellschaft für Pädiatrische Pneumologie e. V. (GPP), Bender S; Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie e. V. (DGKJP), Berner R, de Laffolie J; Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. (GPGE), Dingemann J; Deutsche Gesellschaft für Kinderchirurgie e. V. (DGKCH), Heinicke D; Bündnis Kinder- und Jugendreha e. V. (BKJR), Haas JP; Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), Hufnagel M, Hummel T; Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V. (DGHNO-KHC), Huppertz HI; Deutsche Akademie für Kinder- und Jugendmedizin (DAKJ), Knuf M, Kobbe R, Lücke T; Gesellschaft für Neuropädiatrie e. V. (GNP), Riedel J; Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ), Rosenecker J; Deutsche Gesellschaft für Pädiatrische Rehabilitation und Prävention e. V. (DGpRP), Wölfle J; Deutsche Gesellschaft für Kinderendokrinologie und -diabetologie e. V. (DGKED), Schneider B; Deutsche Gesellschaft für Schlafforschung und Schlafmedizin e. V. (DGSM), Schneider D; Deutsche Gesellschaft für Kinder- und Jugendmedizin e. V. (DGKJ), Schriever V; Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V. (DGHNO-KHC), Schroeder A; Gesellschaft für Neuropsychologie (GNP), Stojanov S, Tenenbaum T, Trapp S; Berufsverband der Kinder- und Jugendärzte e. V. (BVKJ), Vilser D; Deutsche Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler e. V. (DGPK), Brinkmann F, Behrends U. Einheitliche Basisversorgung von Kindern und Jugendlichen mit Long COVID: Stellungnahme einer multidisziplinären Arbeitsgruppe der DGKJ-Konvent-Gesellschaften (Stand: Februar 2022) [Recommendation for standardized medical care for children and adolescents with long COVID]. Monatsschr Kinderheilkd. 2022 May 25;170(6):1-9. German. doi: 10.1007/s00112-021-01408-1. Epub ahead of print. PMID: 35637934; PMCID: PMC9131710. https://pubmed.ncbi.nlm.nih.gov/35637934/ (Full article available in German)

Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the US

Abstract:

Importance: Identifying the associations between severe COVID-19 and individual cardiovascular conditions in pediatric patients may inform treatment.

Objective: To assess the association between previous or preexisting cardiovascular conditions and severity of COVID-19 in pediatric patients.

Design, setting, and participants: This retrospective cohort study used data from a large, multicenter, electronic health records database in the US. The cohort included patients aged 2 months to 17 years with a laboratory-confirmed diagnosis of COVID-19 or a diagnosis code indicating infection or exposure to SARS-CoV-2 at 85 health systems between March 1, 2020, and January 31, 2021.

Exposures: Diagnoses for 26 cardiovascular conditions between January 1, 2015, and December 31, 2019 (before infection with SARS-CoV-2).

Main outcomes and measures: The main outcome was severe COVID-19, defined as need for supplemental oxygen or in-hospital death. Mixed-effects, random intercept logistic regression modeling assessed the significance and magnitude of associations between 26 cardiovascular conditions and COVID-19 severity. Multiple comparison adjustment was performed using the Benjamini-Hochberg false discovery rate procedure.

Results: The study comprised 171 416 pediatric patients; the median age was 8 years (IQR, 2-14 years), and 50.28% were male. Of these patients, 17 065 (9.96%) had severe COVID-19. The random intercept model showed that the following cardiovascular conditions were associated with severe COVID-19: cardiac arrest (odds ratio [OR], 9.92; 95% CI, 6.93-14.20), cardiogenic shock (OR, 3.07; 95% CI, 1.90-4.96), heart surgery (OR, 3.04; 95% CI, 2.26-4.08), cardiopulmonary disease (OR, 1.91; 95% CI, 1.56-2.34), heart failure (OR, 1.82; 95% CI, 1.46-2.26), hypotension (OR, 1.57; 95% CI, 1.38-1.79), nontraumatic cerebral hemorrhage (OR, 1.54; 95% CI, 1.24-1.91), pericarditis (OR, 1.50; 95% CI, 1.17-1.94), simple biventricular defects (OR, 1.45; 95% CI, 1.29-1.62), venous embolism and thrombosis (OR, 1.39; 95% CI, 1.11-1.73), other hypertensive disorders (OR, 1.34; 95% CI, 1.09-1.63), complex biventricular defects (OR, 1.33; 95% CI, 1.14-1.54), and essential primary hypertension (OR, 1.22; 95% CI, 1.08-1.38). Furthermore, 194 of 258 patients (75.19%) with a history of cardiac arrest were younger than 12 years.

Conclusions and relevance: The findings suggest that some previous or preexisting cardiovascular conditions are associated with increased severity of COVID-19 among pediatric patients in the US and that morbidity may be increased among individuals children younger than 12 years with previous cardiac arrest.

Source: Ehwerhemuepha L, Roth B, Patel AK, Heutlinger O, Heffernan C, Arrieta AC, Sanger T, Cooper DM, Shahbaba B, Chang AC, Feaster W, Taraman S, Morizono H, Marano R. Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the US. JAMA Netw Open. 2022 May 2;5(5):e2211967. doi: 10.1001/jamanetworkopen.2022.11967. PMID: 35579899. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792374 (Full text)

Persistent COVID-19 symptoms in a community study of 606,434 people in England

Abstract:

Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n = 508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms.

At 12 weeks in rounds 3-5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3-5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.

Source: Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022 Apr 12;13(1):1957. doi: 10.1038/s41467-022-29521-z. PMID: 35413949; PMCID: PMC9005552. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005552/ (Full text)

The teachings of Long COVID

Long COVID is the state of not recovering several weeks following acute infection with SARS-CoV-2, whether tested or not. It is a patient-made umbrella term for this condition, which may involve multiple pathologies. The underlying mechanisms are still largely unknown, but hypotheses include inflammatory or autoimmune processes, organ damage and scarring, hypercoagulability, endothelial damage, or even persistent viral protein in the body,. Based on the UK Office for National Statistics (ONS) estimates, the prevalence of Long COVID is around 1 in 7 people at three months from the infection, and it is most common in working-age adults, but also occurs in other age groups, including children. More recent ONS figures indicate that there are 376,000 people in the UK who have had Long COVID for at least one year. It has a wide range of symptoms, but the most common are exhaustion, breathlessness, muscle aches, cognitive dysfunction, including poor memory and difficulty concentrating, headache, palpitations, dizziness and chest tightness or heaviness. The nature of the symptoms is mostly relapsing, resulting in significant dysfunction and limitations in a relatively large proportion of sufferers,.

It seemed nobody had thought about the enormous implications of chronic disease as a result of letting SARS-CoV-2 spread through the community, assuming it would all be fine for those classed as non-vulnerable.

During the past year, I have been advocating for Long COVID, as well as doing research on it. I experienced it after developing COVID-19 symptoms in March 2020. My acute illness was not severe, so I did not go to hospital, as the medical advice at the time was to isolate at home, and that, like flu-like illness, one would be completely recovered within a week or two. This also meant I did not have access to testing to confirm infection, as community testing stopped in the UK on March 12, 2020. Although I felt improvements, the illness did not go away after several weeks. Some of my symptoms, the chest heaviness, muscle aches, and fatigue, remained fluctuating for months, while new symptoms, such as palpitations, also appeared. Every time I felt it was almost over, symptoms came back. I started recognising and avoiding some of the activities that triggered the symptoms, but I could not always work out what caused the relapses.

The constant cycle of disappointment at not completely recovering was devastating. The never-ending symptoms and their effect on my daily activities were a cause for worry. It was somewhat reassuring that so many others were posting similar stories on social media, but it was a struggle to get Long COVID recognised by governments and national health agencies as a serious problem back then. It seemed nobody had thought about the enormous implications of chronic disease as a result of letting SARS-CoV-2 spread through the community, assuming it would all be fine for those classed as non-vulnerable. As I wrote in a previous piece ‘death is not the only thing to count in this pandemic, we must count lives changed’. I urged public health agencies to quantify and define Long COVID,. Over the last year, I have been engaging in forums to raise awareness on its significance, impact, and scale. I have also worked with other people living with Long COVID to research the characteristics of the illness. Through this journey, I have learnt some lessons that apply not only to Long COVID but more widely to pandemic preparedness, equality, and social justice, and how medicine and society deal with similar chronic conditions.

The first lesson was how much our understanding, as scientists or physicians, can be enriched by patient experience. This includes genuine patient involvement in all stages of science and healthcare design, but may also include us wearing the two hats of patient and expert. Unfortunately, a lot of healthcare professionals and health scientists across the world caught SARS-CoV-2 with many suffering the consequences of Long COVID. In the UK, 3.6% of all healthcare staff were estimated to have Long COVID. The experience of the illness not only brings deep understanding and appreciation of its real-life impact, but also of the questions that need answering. People with lived experience must have a central role in shaping the research and services agenda because they are experts in living with the disease. Even with substantial patient involvement in shaping care and research, some sections of society will always have more representation in decision-making forums than others. Therefore, without seeking insight and input from those usually unheard, our response will always be inadequate.

Another lesson was that we need systems in place that measure morbidity in addition to mortality. We have always been better at measuring the acute over the chronic, but it is the latter that has the most long-lasting impact on societies. At the beginning of the pandemic, long-term illness and ensuing disability due to COVID were completely dismissed and did not shape policy decisions. This is partly because they were not adequately quantified, and the models informing policy and public opinion used short-term outcomes of hospitalisation and death. It is disheartening to still frequently see recovery confused with short-term survival or hospital discharge. We need systems to record recovery and continued illness following infection, accurately and universally. Disease registers have been employed for other chronic conditions such as cancer and could prove very valuable for Long COVID as well as other post-viral illnesses.

A third lesson was that we must challenge stereotyped narratives that tend to dominate the Long COVID discourse. Long COVID has been predominately pictured as something that mainly ails middle-aged women. However, the difference in the prevalence between women and men seems relatively small (15% vs 13% according to ONS estimates). Women have experienced not being believed about their symptoms with other similar chronic conditions, such as chronic fatigue syndrome and fibromyalgia. This has the potential to lead to stigma and institutional discrimination. When the dismissal of concerns and symptoms by service providers and employers is compounded by demographic, ethnic, social, and economic pre-existing structural disparities, the injustice is exacerbated. The stigma can become internalised potentially depriving people with lived experience of Long Covid from recognition, support, and services because they do not want to face the dismissal, disbelief, and denial. We must not repeat past mistakes of stereotyping and pushing those already disadvantaged away from seeking help.

To avoid the effect of stereotyping, stigma, and variation in recognition, and to measure the effect of Long COVID on systems, the economy, and the whole of society, we need to agree case definitions as soon as possible. Science on the topic is evolving and case definitions will need to be frequently updated, but we cannot afford to wait. People living with Long COVID need proper clinical assessments, medical investigations, and a diagnosis. A diagnosis is necessary not only for treatment and rehabilitation purposes, but also to maintain livelihoods. Without it, people with what are considered ‘unexplained symptoms’ may lose out on employment rights and benefits, leading to financial hardship that can exacerbate their illness. The diagnosis could simply be an umbrella term like Long COVID that encompasses some uncertainty about how it manifests. A case definition for research can be more stringent than that for the purpose of surveillance. Criteria used for clinical diagnosis must be the most inclusive because people’s lives depend on them (11). The case definitions must be based on clinical assessment and not be dependent on laboratory tests, since there is a range of problems with these, including access, affordability, and accuracy.

Though perhaps the most important lesson that Long COVID taught me, and I hope it can teach others, is that showing humility in the face of uncertainty is the first right step to deal with a phenomenon that we do not fully understand. Throughout the pandemic, I have seen uncertainty in science, medicine and public health communicated with certainty. This has been largely damaging, and that includes the case of Long COVID. The possibility that COVID-19 might not be a short illness for all, was entirely dismissed from public communication, despite multiple examples of devastating long-lasting effects of other viruses. Assumptions have been made about the nature, cause, and mode of treatment of Long COVID, despite a lack of evidence to support them. Acknowledging we do not know everything does not mean inaction. It means informed action with honesty, which may involve applying the precautionary principle until we know more.

The pandemic is not over, and it is peaking in many parts of the world. Therefore, preventing Long COVID should be high on everyone’s agenda. Long COVID messaging must be incorporated in all prevention policies including vaccination and non-pharmacological interventions. The effect of COVID-19 vaccines in modifying the course of Long COVID is still uncertain and under investigation. In the meantime, the primary purpose of vaccination in relation to Long COVID should be to prevent it in those who do not have it, and to prevent re-infection in those who do.

As for me, I am grateful that my Long COVID has been a lighter guest in 2021, with less frequent and shorter visits. This is sadly not the story of everybody who is living with it, with many not improving, or deteriorating over time. Let us, for their sake, not repeat past mistakes and learn from the global experience of this phenomenon to help all people living with similar under-researched chronic conditions, and prevent more from happening.

Read the full article HERE.

Source: Alwan NA. The teachings of Long COVID. Commun Med (Lond). 2021 Jul 12;1:15. doi: 10.1038/s43856-021-00016-0. PMID: 35602198; PMCID: PMC9053272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053272/ (Full text)

Differences in clinical presentation with long covid following community and hospital infection, and associations with all-cause mortality: English sentinel network database study

Abstract:

Background: Most studies of long covid (symptoms of COVID-19 beyond 4 weeks) have focused on people hospitalised in their initial illness. Long covid is thought to be under-recorded in UK primary care electronic records.

Objective: We sought to determine which symptoms people present to primary care following COVID-19, and whether presentation differs in people who were not hospitalised, and post-long covid mortality.

Methods: We used routine data from the nationally representative Primary Care Sentinel Cohort of the Oxford-Royal College of General Practitioners Research and Surveillance Centre (N=7.4million), applying a pre-defined long covid phenotype and grouped by whether the illness index was in hospital or community. We included COVID-19 cases between 1st-March-2020 and 1st-April-2021. We conducted a before and after analysis of pre-specified long covid symptoms identified by the Office of National Statistics, comparing symptoms presented between one and six months after their index infection matched with the same months one year previously. We conducted logistic regression analysis, quoting odds ratios with 95% confidence intervals, reporting differences between those with an index community infection compared to those who had been hospitalised, and separately associations with all-cause mortality.

Results: 5.6% (416,505/7,396,702) and 1.8% (7,623/416,505) of patients respectively had a coded diagnosis of COVID-19 and diagnosis or referral for long covid. People coded as having long covid were significantly more likely to have presented the pre-specified symptoms after vs before COVID-19 infection (odds ratios 2.66 [2.46-2.88] for those with index community infection and 2.42 [2.03-2.89] for those hospitalised). Following an index community infection, patients were more likely to present with non-specific symptoms (odds ratio 3.44 [3.00-3.95], P<.001) than following a hospital admission (odds ratio 2.09 [1.56-2.80], P<.001). Mental health sequelae were more commonly associated with hospital admission index infections (odds ratio 2.21 [1.64-2.96]) compared to community (odds ratio 1.36 [1.21-1.53], P<.001). People presenting to primary care following hospital infection were more likely to be male (odds ratio 1.43 [1.25-1.64], P<.001), more socioeconomically deprived (odds ratio 1.42 [1.24-1.63], P<.001); and to have multi-morbidity (odds ratio 1.41 [1.26-1.57], P<.001) than those presenting after an index community infection. All-cause mortality in people with long covid was associated with increasing age; male gender (odds ratio 3.32 [1.34-9.24], P<.01) and higher multi-morbidity score (odds ratio 2.11 [1.34-3.29], P<.001). One or more vaccine doses was associated with reduced odds of mortality (odds ratio 0.10 [0.03-0.35], P<.001).

Conclusions: The low percentage of people recorded as having long covid following COVID-19 reflects either low prevalence or under-recording. The characteristics and comorbidities of those presenting with long covid following a community infection are different from those who were hospitalised with their index infection. This study provides insights into the presentation of long covid in primary care and implications for workload.

Source: Meza-Torres B, Delanerolle G, Okusi C, Mayer N, Anand S, McCartney J, Gatenby P, Glampson B, Chapman M, Curcin V, Mayer E, Joy M, Greenhalgh T, Delaney B, de Lusignan S. Differences in clinical presentation with long covid following community and hospital infection, and associations with all-cause mortality: English sentinel network database study. JMIR Public Health Surveill. 2022 May 17. doi: 10.2196/37668. Epub ahead of print. PMID: 35605170.  https://preprints.jmir.org/preprint/37668/accepted (Full text)

Symptoms and signs of long COVID: A rapid review and meta-analysis

Abstract:

Background: Long COVID is defined as symptoms and signs related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are present at least four weeks following acute infection. These symptoms and signs are poorly characterised but may be associated with significant morbidity. We sought to synthesise the evidence on their incidence to guide future research, policy and practice.

Methods: We searched Medline and Embase for longitudinal cohort studies from January 2020 to July 2021 that investigated adults with long COVID at least four weeks after acute infection. Risk of bias was assessed using the Joanna Briggs Institute checklist for cohort studies. Random-effects meta-analyses were performed with subgroup analysis by follow-up time (4-12 vs more than 12 weeks).

Results: 19 studies were included, 13 of which included patients hospitalised with COVID-19. The total sample size was 10 643 and the follow-up time ranged from 30 to 340 days. Risk of bias was assessed as high in one study, moderate in two studies and low in the remaining 16 studies. The most common symptoms and signs seen at any time point in long COVID were fatigue (37%; 95% confidence interval (CI) = 23-55), dyspnoea (21%; 95% CI = 14-30), olfactory dysfunction (17%; 95% CI = 9-29), myalgia (12%; 95% CI = 5-25), cough (11%; 95% CI = 6-20) and gustatory dysfunction (10%; 95% CI = 7-17). High heterogeneity was seen for all meta-analyses and the presence of some funnel plot asymmetry may indicate reporting bias. No effect of follow-up time was found for any symptom or sign included in the subgroup analysis.

Conclusions: We have summarised evidence from longitudinal cohort studies on the most common symptoms and signs associated with long COVID. High heterogeneity seen in the meta-analysis means pooled incidence estimates should be interpreted with caution. This heterogeneity may be attributable to studies including patients from different health care settings and countries.

Source: Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review and meta-analysis. J Glob Health. 2022 May 21;12:05014. doi: 10.7189/jogh.12.05014. PMID: 35596571.https://jogh.org/2022/jogh-12-05014 (Full text)

Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence

Abstract:

Background: SARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19, and the impact of AAA1 on the inflammatory response and symptoms persistence.

Methods: All serologies were assessed at one, three, six, and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-α and-γ production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro.

Results: AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3rd month on, AAA1 levels predicted persistent respiratory symptoms (area under the curves 0.72-0.74; p<0.001), independently of disease severity, age and gender (adjusted odds ratios 4.81-4.94; p=0.02), while anti-SARS-CoV-2 serologies did not. AAA1 increased IFN-α production by HMDMs (p=0.03), without affecting the IFN-γ response.

Conclusion: COVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined

Source: L’Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, Guessous I, Eberhardt CS, Huttner A, Posfay-Barbe KM, Yerly S, Siegrist CA, Kaiser L, Vuilleumier N. Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. Eur J Clin Invest. 2022 May 22:e13818. doi: 10.1111/eci.13818. Epub ahead of print. PMID: 35598178.  https://pubmed.ncbi.nlm.nih.gov/35598178/ (Full text available as PDF file)

Are vaccines a potential treatment for long covid?

Vaccines in the covid-19 pandemic have been a game changer in reducing rates of SARS-CoV-2 infection and hospital admission for, and death with, covid-19. They also reduce the chance of developing long covid by about half among people who are vaccinated before they develop covid-19.1 However, the effect of vaccines for people who already have long covid is a contentious area for both patients and healthcare professionals. In a linked paper, Ayoubkhani and colleagues (doi:10.1136/bmj-2021-069676) report findings from the largest published study on this topic to date.2 From a random sample of the UK population, they identified 28 356 adults (18-69 years) who were vaccinated after a positive SARS-CoV-2 test result, of whom 6729 (23.7%) reported long covid symptoms (>12 weeks) of any severity at least once during follow-up. Participants were followed for seven months to determine the relationship between vaccination, long covid, and symptom profiles after the first and second dose of either an adenovirus vector or mRNA vaccine.2

Read the rest of this article HERE.

Source: Manoj Sivan. Are vaccines a potential treatment for long covid? Cite this as: BMJ 2022;377:o988. https://www.bmj.com/content/377/bmj.o988.full (Full text)

Pathophysiology and mechanism of long COVID: a comprehensive review

Abstract:

Background: After almost 2 years of fighting against SARS-CoV-2 pandemic, the number of patients enduring persistent symptoms long after acute infection is a matter of concern. This set of symptoms was referred to as “long COVID”, and it was defined more recently as “Post COVID-19 condition” by the World health Organization (WHO). Although studies have revealed that long COVID can manifest whatever the severity of inaugural illness, the underlying pathophysiology is still enigmatic.

Aim: To conduct a comprehensive review to address the putative pathophysiology underlying the persisting symptoms of long COVID.

Method: We searched 11 bibliographic databases (Cochrane Library, JBI EBP Database, Medline, Embase, PsycInfo, CINHAL, Ovid Nursing Database, Journals@Ovid, SciLit, EuropePMC, and CoronaCentral). We selected studies that put forward hypotheses on the pathophysiology, as well as those that encompassed long COVID patients in their research investigation.

Results: A total of 98 articles were included in the systematic review, 54 of which exclusively addressed hypotheses on pathophysiology, while 44 involved COVID patients. Studies that included patients displayed heterogeneity with respect to the severity of initial illness, timing of analysis, or presence of a control group. Although long COVID likely results from long-term organ damage due to acute-phase infection, specific mechanisms following the initial illness could contribute to the later symptoms possibly affecting many organs. As such, autonomic nervous system damage could account for many symptoms without clear evidence of organ damage. Immune dysregulation, auto-immunity, endothelial dysfunction, occult viral persistence, as well as coagulation activation are the main underlying pathophysiological mechanisms so far.

Conclusion: Evidence on why persistent symptoms occur is still limited, and available studies are heterogeneous. Apart from long-term organ damage, many hints suggest that specific mechanisms following acute illness could be involved in long COVID symptoms.

KEY MESSAGES:

  • Long-COVID is a multisystem disease that develops regardless of the initial disease severity. Its clinical spectrum comprises a wide range of symptoms.
  • The mechanisms underlying its pathophysiology are still unclear. Although organ damage from the acute infection phase likely accounts for symptoms, specific long-lasting inflammatory mechanisms have been proposed, as well.
  • Existing studies involving Long-COVID patients are highly heterogeneous, as they include patients with various COVID-19 severity levels and different time frame analysis, as well.

Source: Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473-1487. doi: 10.1080/07853890.2022.2076901. PMID: 35594336; PMCID: PMC9132392. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132392/ (Full text)